• Roche's first FDA-approved tumour-agnostic medicine worldpharmanews
    August 19, 2019
    Roche announced that the US Food and Drug Administration (FDA) has approved Rozlytrek™ (entrectinib) for the treatment of adults with ROS1-positive, metastatic non-small cell lung cancer (NSCLC).
PharmaSources Customer Service